Clinical Research

Construction and verification of multi⁃factor prediction model for refractory mycoplasma pneumoniae pneumonia in children

  • Zhiqing XIAO ,
  • Xue WU ,
  • Rui QIU ,
  • Jinghan CHI ,
  • Shaodong HUA ,
  • Bin ZHU ,
  • De CHANG
Expand
  • Department of Respiratory and Critical Care Medicine,the eight Medical Center of Chinese PLA General Hospital,Beijing 100091,Beijing,China
    Department of Respiratory and Critical Care Medicine,the Seventh Medical Center of Chinese PLA General Hospital,Beijing 100007,Beijing,China

Received date: 2025-01-25

  Online published: 2025-07-18

Abstract

Objective To comprehensively analyze the clinical characteristics and risk factors of children with refractory mycoplasma pneumonia (RMPP), precisely identify the joint predictors in these children, and construct a prediction model. This aims to offer a scientific foundation for the early identification of RMPP and the formulation of accurate treatment and medication strategies. Methods A retrospective analysis was performed on the clinical data of 282 children diagnosed with mycoplasma pneumoniae pneumonia (MPP) who were admitted to the Pediatric Department of the Seventh Medical Center of the Chinese People's Liberation Army General Hospital between August 1, 2023, and February 29, 2024. Among these children, 119 with RMPP were classified into the RMPP group, while the remaining 163 with general MPP (GMPP) were assigned to the GMPP group. The clinical data of both groups, encompassing age, gender, duration of fever, symptoms, laboratory test indices, chest imaging data, complications, etc., were compared. A logistic probability model (LogP model) for joint application was constructed. The discriminatory ability of the model was evaluated using the area under the receiver operating characteristic (ROC) curve, and the calibration of the model was assessed by means of a calibration curve. Results In comparison with the GMPP group, children in the RMPP group exhibited a significantly longer duration of fever (P = 0.002). Moreover, they had a higher incidence of complications, including myocardial damage and coagulation dysfunction (P < 0.05). Regarding inflammatory markers, the levels of C-reactive protein (CRP), procalcitonin (PCT), and lactate dehydrogenase (LDH) were notably elevated in the RMPP group (P < 0.05), whereas the level of albumin (Alb) was lower (P = 0.001). In the RMPP group, the levels of interleukin-2 (IL-2), interleukin-5 (IL-5), interleukin-8 (IL-8), interleukin-1β (IL-1β), and D-Dimer were increased, while the levels of interleukin-6 (IL-6) and interleukin-17 (IL-17) were decreased (P < 0.05). Chest computed tomography (CT) scans revealed a higher proportion of lung consolidation, pleural effusion, and atelectasis in the RMPP group (P < 0.05). Multivariate logistic regression analysis demonstrated that CRP, total bilirubin (T-BIL), LDH, IL-17, and prothrombin time (PT) were independent risk factors for RMPP (P < 0.05). The receiver operating characteristic (ROC) predictive model established based on these factors had an area under the curve (AUC) of 0.787 (95% confidence interval [CI]: 0.693 ~ 0.880), with a cutoff value of 0.421, a sensitivity of 0.786, and a specificity of 0.660. The calibration curve indicated that the predicted probability matched well with the reference probability, and there was no statistical difference in the results of the Hosmer-Lemeshow test (P > 0.05). Conclusions The clinical features of children with RMPP are predominantly characterized by prolonged fever, moderate lung lesions, other organ injuries, and high inflammatory markers. CRP, T-BIL, LDH, IL-17, and PT can act as independent risk factors for RMPP.

Cite this article

Zhiqing XIAO , Xue WU , Rui QIU , Jinghan CHI , Shaodong HUA , Bin ZHU , De CHANG . Construction and verification of multi⁃factor prediction model for refractory mycoplasma pneumoniae pneumonia in children[J]. The Journal of Practical Medicine, 2025 , 41(13) : 2004 -2010 . DOI: 10.3969/j.issn.1006-5725.2025.13.009

References

[1] MEYER SAUTEUR P M, UNGER W W J, VAN ROSSUM A M C, et al. The Art and Science of Diagnosing Mycoplasma pneumoniae Infection[J]. Pediatr Infect Dis J, 2018, 37(11): 1192-1195. doi:10.1097/inf.0000000000002171
[2] WAITES K B, XIAO L, LIU Y, et al. Mycoplasma pneumoniae from the Respiratory Tract and Beyond[J]. Clin Microbiol Rev, 2017, 30(3): 747-809. doi:10.1128/cmr.00114-16
[3] 许颖, 苏艳琦, 郎会利. 肺炎支原体肺炎患儿血清维生素A与维生素E水平调查[J].中国中西医结合儿科学, 2019, 11(4): 351-353.
[4] 方俊梅, 包晓珍. 丙种球蛋白辅助治疗儿童难治性肺炎支原体肺炎的临床疗效[J].中国中西医结合儿科学, 2020, 12(3): 233-236. doi:10.3969/j.issn.1674-3865.2020.03.014
[5] 赵顺英, 钱素云, 陈志敏, 等. 儿童肺炎支原体肺炎诊疗指南(2023年版)[J].传染病信息, 2023, 36(4): 291-297. doi:10.12372/jcp.2023.22e0475
[6] 王亨, 赵顺英. 儿童难治性肺炎支原体肺炎的发病机制和诊治研究进展[J].世界临床药物, 2020, 41(5): 389-398.
[7] 鲍汝英, 徐国成. 儿童难治性肺炎支原体肺炎的发病机制及治疗进展[J].齐齐哈尔医学院学报, 2022, 43(13): 1274-1278.
[8] 刘帅帅, 马静, 张忠晓, 等. 儿童肺炎支原体坏死性肺炎的早期预测指标[J].中华实用儿科临床杂志, 2021(8): 601-604. doi:10.3760/cma.j.cn101070-20191231-01327
[9] JIANG Z, LI S, ZHU C, et al. Mycoplasma pneumoniae Infections: Pathogenesis and Vaccine Development[J]. Pathogens, 2021, 10(2):119. doi:10.3390/pathogens10020119
[10] CHOI Y J, CHUNG E H, LEE E, et al. Clinical Characteristics of Macrolide-Refractory Mycoplasma pneumoniae Pneumonia in Korean Children: A Multicenter Retrospective Study[J]. J Clin Med, 2022, 11(2):306. doi:10.3390/jcm11020306
[11] ZHANG Y, ZHOU Y, LI S, et al. The Clinical Characteristics and Predictors of Refractory Mycoplasma pneumoniae Pneumonia in Children[J]. PLoS One, 2016, 11(5): e0156465. doi:10.1371/journal.pone.0156465
[12] KAWAMATA R, YOKOYAMA K, SATO M, et al. Utility of serum ferritin and lactate dehydrogenase as surrogate markers for steroid therapy for Mycoplasma pneumoniae pneumonia[J]. J Infect Chemother, 2015, 21(11): 783-789. doi:10.1016/j.jiac.2015.07.009
[13] JIANG Y, WANG W, ZHANG Z, et al. Serum amyloid a, C-reactive protein, and procalcitonin levels in children with Mycoplasma pneumoniae infection[J]. J Clin Lab Anal, 2022, 36(3): e24265. doi:10.1002/jcla.24265
[14] JIN H L, ZHAN L, MEI S F, et al. Serum Cytokines and FeNO in School-Aged Children with Mycoplasma pneumoniae Pneumonia[J]. Med Sci Monit, 2020, 26: e923449. doi:10.12659/msm.923449
[15] YU M, ZHANG Q, YAN H. Cytokines and refractory mycoplasma pneumoniae pneumonia in children: a systematic review[J]. Minerva Pediatr (Torino), 2024, 76(2): 259-267. doi:10.23736/s2724-5276.23.07158-6
[16] FAN F, LV J, YANG Q, et al. Clinical characteristics and serum inflammatory markers of community-acquired mycoplasma pneumonia in children[J]. Clin Respir J, 2023, 17(7): 607-617. doi:10.1111/crj.13620
[17] FAN H, LU B, YANG D, et al. Distribution and Expression of IL-17 and Related Cytokines in Children with Mycoplasma pneumoniae Pneumonia[J]. Jpn J Infect Dis, 2019, 72(6): 387-393. doi:10.7883/yoken.jjid.2019.113
[18] LI T, YU H, HOU W, et al. Evaluation of variation in coagulation among children with Mycoplasma pneumoniae pneumonia: a case-control study[J]. J Int Med Res, 2017, 45(6): 2110-2118. doi:10.1177/0300060517709613
[19] ZHOU Y, WANG J, CHEN W, et al. Impact of viral coinfection and macrolide-resistant mycoplasma infection in children with refractory Mycoplasma pneumoniae pneumonia[J]. BMC Infect Dis, 2020, 20(1): 633. doi:10.1186/s12879-020-05356-1
Outlines

/